arginine has been researched along with exenatide in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Egido, EM; Hernández, R; Marco, J; Silvestre, RA | 3 |
| Brendel, MD; Bretzel, RG; Jahr, H; Mergler, S; Plöckinger, U; Singh, V; Strowski, MZ; Wiedenmann, B; Zacharias, S | 1 |
| Bunck, MC; Cornér, A; Deng, W; Diamant, M; Eliasson, B; Heine, RJ; Kendall, DM; Malloy, JL; Shaginian, RM; Smith, U; Taskinen, MR; Yki-Järvinen, H | 1 |
| Kim, PH; Kim, SW; Lee, M | 1 |
| Fukami, K; Ishibashi, Y; Maeda, S; Matsui, T; Nishino, Y; Ojima, A; Takeuchi, M; Yamagishi, S | 1 |
| Carbone, A; Ciccarelli, L; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 1 |
| Balabanyan, VY; Kashkin, VA; Makarov, VG; Makarova, MN; Muzhikyan, AА; Shekunova, EV | 1 |
| Anderson, JN; Bao, Y; Bartlett, JR; Bissonnette, S; Briant, AR; Carcel, C; Chan, K; Chen, H; Chen, L; Cheng, C; Chrétien, M; Conway Fitzgerald, A; Cyr, Y; Du, Y; El-Sayed, YY; Endo, T; Faraj, M; Fujimoto, K; Girsen, A; Goto, H; Hashimoto, D; Hayasaka, K; Hayase, E; Herrmann, N; Hidaka, D; Holst, JJ; Igbinosa, I; Iijima, H; Jeandidier, N; Jeong, DY; Jeong, GT; Joubert, M; Kagawa, I; Kahata, K; Kaushik, LK; Kim, SK; Kim, SR; Kuang, Y; Laird, M; Lamantia, V; Li, P; Li, Y; Li, Z; Lindsay, SE; Liu, X; Loizon, E; Lu, Z; Lyell, DJ; Ma, J; Magnani, CJ; Mahalingam, AK; Mandal, N; Mayer, G; Michimata, R; Ngo Sock, ET; Okada, K; Onozawa, M; Opigez, V; Palanisamy, M; Parienti, JJ; Park, YR; Pavlikova, B; Peyro Saint Paul, L; Ramsahye, N; Reyes, GA; Reznik, Y; Richardson, MT; Samo, IA; Sarkar, R; Shendge, AK; Shimizu, C; Shiratori, S; Steinberg, JR; Sugita, J; Sukwong, P; Sun, X; Sunagoya, K; Sunwoo, IY; Svendsen, B; Tang, L; Tang, Z; Teshima, T; Totée, C; Turner, BE; Unno, M; Vidal, H; Wang, C; Wang, M; Wang, S; Wang, X; Wang, Z; Wassef, H; Weeks, BT; Wong Chi Man, M; Xu, C; Xu, W; Yamamoto, S; Yu, H; Zhang, WY; Zhang, X; Zhong, Y | 1 |
| Kanemoto, S; Miyata, K; Sakuma, S; Shigeno, K; Tomono, T; Ukawa, M; Yagi, H | 1 |
| Bełtowski, J; Czechowska, G; Fornal, E; Góralczyk, A; Korolczuk, A; Kozub, A; Marzec-Kotarska, B; Nikolaichuk, H; Pradiuch, A; Stachniuk, A; Trzpil, A; Wójcicka, G | 1 |
1 review(s) available for arginine and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for arginine and exenatide
| Article | Year |
|---|---|
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Topics: Arginine; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Secretion; Insulin-Secreting Cells; Insulin, Long-Acting; Kinetics; Male; Metformin; Middle Aged; Peptides; Venoms | 2009 |
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Topics: Aged; Arginine; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; C-Peptide; Chimerin Proteins; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Exenatide; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Male; Metformin; Middle Aged; Peptides; Resistin; Risk Factors; Serpins; Venoms | 2013 |
Topics: Adipose Tissue, White; Adult; Aged; Air Pollutants; Animals; Anti-Inflammatory Agents; Arginine; bcl-2-Associated X Protein; Biofuels; Biological Products; Blood Glucose; Breast Neoplasms; Caspases; CD36 Antigens; Cell Communication; Cell Proliferation; Cell Survival; Cooking; Cross-Sectional Studies; Databases, Factual; Diabetes Mellitus, Type 2; Diphtheria Toxin; Double-Blind Method; Exenatide; Extracellular Polymeric Substance Matrix; Feasibility Studies; Female; Filgrastim; Fruit; Galactose; Gene Deletion; Gene Knockdown Techniques; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Glycated Hemoglobin; Hematopoietic Stem Cell Mobilization; Household Articles; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Lung; Lymphoma; Male; Metals, Heavy; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Nanoparticles; Neoplasms; Obesity; Obstetrics; Odds Ratio; Oxygen; Peripheral Blood Stem Cell Transplantation; Photochemotherapy; Plant Extracts; Polyethylene Glycols; Polyglutamic Acid; Porosity; Postprandial Period; Prospective Studies; Quality of Life; Receptors, Glucagon; Receptors, LDL; Receptors, Somatostatin; Registries; Rhodophyta; Rhodotorula; Risk Factors; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Signal Transduction; Somatostatin; Stilbenes; Terminalia; Treatment Outcome; United States; Venoms | 2021 |
9 other study(ies) available for arginine and exenatide
| Article | Year |
|---|---|
Exendin-4 dose-dependently stimulates somatostatin and insulin secretion in perfused rat pancreas.
Topics: Animals; Arginine; Carbachol; Cysteamine; Dose-Response Relationship, Drug; Exenatide; Glucose; In Vitro Techniques; Insulin; Insulin Secretion; Male; Pancreas; Peptides; Perfusion; Rats; Rats, Wistar; Somatostatin; Somatostatin-Secreting Cells; Venoms | 2004 |
Tungstate stimulates insulin release and inhibits somatostatin output in the perfused rat pancreas.
Topics: Animals; Arginine; Cysteamine; Exenatide; Glucose; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Male; Pancreas; Peptides; Perfusion; Rats; Rats, Wistar; Somatostatin; Tolbutamide; Tungsten Compounds; Venoms | 2005 |
Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets.
Topics: Arginine; Exenatide; Female; Glucagon; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Membrane Proteins; Middle Aged; Organ Culture Techniques; Peptides; Receptors, Somatostatin; Venoms | 2007 |
Kisspeptin-13 inhibits insulin secretion without affecting glucagon or somatostatin release: study in the perfused rat pancreas.
Topics: Animals; Arginine; Carbachol; Dose-Response Relationship, Drug; Exenatide; Glucagon; In Vitro Techniques; Insulin; Insulin Antagonists; Insulin Secretion; Kisspeptins; Male; Pancreas; Peptides; Pertussis Toxin; Proteins; Rats; Rats, Wistar; Somatostatin; Venoms | 2008 |
Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.
Topics: Animals; Arginine; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; DNA; Drug Carriers; Exenatide; Gene Expression; Genetic Therapy; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Peptides; Plasmids; Polymers; Transcription, Genetic; Venoms | 2012 |
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Topics: Animals; Arginine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Evaluation, Preclinical; Exenatide; Gene Expression Regulation, Enzymologic; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycation End Products, Advanced; Humans; Hypertrophy; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Kidney Tubules; Macrophages; Male; Peptides; Protein-Arginine N-Methyltransferases; Rats; Rats, Wistar; Reactive Oxygen Species; Receptor for Advanced Glycation End Products; Receptors, Glucagon; Receptors, Immunologic; Repressor Proteins; RNA, Messenger; Venoms | 2013 |
Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats.
Topics: Animals; Arginine; Blood Glucose; Diabetic Neuropathies; Dose-Response Relationship, Drug; Exenatide; Gene Expression Regulation; Glycated Hemoglobin; Hyperalgesia; Insulin; Islets of Langerhans; Locomotion; Male; Organ Size; Rats; Rats, Wistar; Sciatic Nerve | 2020 |
Acquisition of absorption-enhancing abilities of cationic oligopeptides with short chain arginine residues through conjugation to hyaluronic acid.
Topics: Animals; Arginine; Cell-Penetrating Peptides; Exenatide; Hyaluronic Acid; Mice; Oligopeptides | 2022 |
The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Chromatography, Liquid; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fibrosis; Fructose; Glucagon-Like Peptide 1; Hypoglycemic Agents; Metabolic Syndrome; Nitric Oxide; Protease Inhibitors; Rats; Sitagliptin Phosphate; Tandem Mass Spectrometry | 2023 |